Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

10.30 -0.06 (-0.58%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,943,145
Open	10.44
Bid (Size)	10.25 (1,100)
Ask (Size)	10.85 (500)
Prev. Close	10.36
Today's Range	10.27 - 11.36
52wk Range	4.350 - 11.36
Shares Outstanding	28,919,810
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Today 8:05 EDT

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

June 25, 2026

From Candel Therapeutics

Via GlobeNewswire

Performance

YTD	+89.3%	+89.3%
1 Month	+21.0%	+21.0%
3 Month	+129.9%	+129.9%
6 Month	+77.6%	+77.6%
1 Year	+103.6%	+103.6%

More News

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

June 02, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 01, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data ↗

May 20, 2026

Via MarketBeat

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

May 15, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at Upcoming Investor Conferences

May 13, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

May 04, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 01, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

April 29, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 02, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

March 17, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

March 12, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

March 09, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 02, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

February 24, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Pricing of Public Offering

February 19, 2026

From Candel Therapeutics

Via GlobeNewswire

Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today ↗

February 19, 2026

Via Stocktwits

Candel Therapeutics Announces Proposed $100 Million Public Offering

February 19, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

February 19, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

February 11, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2026

From Candel Therapeutics

Via GlobeNewswire

Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗

December 05, 2025

Via Stocktwits

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

November 17, 2025

From Candel Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Candel Therapeutics, Inc. - Common Stock publicly traded?

Yes, Candel Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Candel Therapeutics, Inc. - Common Stock trade on?

Candel Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Candel Therapeutics, Inc. - Common Stock?

The ticker symbol for Candel Therapeutics, Inc. - Common Stock is CADL on the Nasdaq Stock Market

What is the current price of Candel Therapeutics, Inc. - Common Stock?

The current price of Candel Therapeutics, Inc. - Common Stock is 10.30

When was Candel Therapeutics, Inc. - Common Stock last traded?

The last trade of Candel Therapeutics, Inc. - Common Stock was at 06/30/26 04:00 PM ET

What is the market capitalization of Candel Therapeutics, Inc. - Common Stock?

The market capitalization of Candel Therapeutics, Inc. - Common Stock is 297.87M

How many shares of Candel Therapeutics, Inc. - Common Stock are outstanding?

Candel Therapeutics, Inc. - Common Stock has 298M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.